Advanced melanoma: adding ziv-aflibercept to IL-2 boosts PFS

  • Tarhini AA & al.
  • Cancer
  • 10 Oct 2018

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Results from a randomized phase 2 study indicate that combined ziv-aflibercept/high-dose interleukin 2 (IL-2) is associated with superior PFS compared with IL-2 alone in patients with inoperable stage III/IV melanoma.

Why this matters

  • This trial supports the use of VEGF inhibitors such as ziv-aflibercept to enhance the therapeutic benefits of IL-2.

Key results

  • Patients treated with combination therapy had improved PFS compared with patients treated with monotherapy (median, 6.9 vs 2.3 months; P=.002).
    • The association between combination therapy and improved PFS was observed in patients with high baseline VEGF (8.7 vs 3.1 months; P=.003), low VEGF (6.9 vs 4.0 months; P=.02), high VEGFR2 (10.2 vs 3.9 months; P=.004), and low VEGFR2 (6.1 vs 1.6 months; P=.0002).
  • Patients treated with combination therapy and those treated with monotherapy had similar OS (median, 26.9 vs 24.2 months; P=.43).
  • Response rates were 22% in patients who received combination therapy and 17% in patients who received monotherapy.
  • Adverse events were consistent with the profiles of IL-2 and ziv-aflibercept monotherapy.

Study design

  • 84 patients with inoperable stage III/IV melanoma, 55 treated with ziv-aflibercept/IL-2 combination therapy, and 29 treated with IL-2-only monotherapy, were analyzed for outcomes.
  • Funding: National Cancer Institute/NIH.

Limitations

  • Small patient sample size.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit